Yohei Takanami
Takeda (United States)(US)
Publications by Year
Research Areas
Helicobacter pylori-related gastroenterology studies, Gastroesophageal reflux and treatments, Bacterial Infections and Vaccines, Pneumonia and Respiratory Infections, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials(2016)124 cited
- → Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication(2021)42 cited
- → Randomized clinical trial: A double‐blind, proof‐of‐concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro‐esophageal reflux disease and partial response to a healing dose of a proton‐pump inhibitor(2022)18 cited
- → Comparison of serum bactericidal and antibody titers induced by two Haemophilus influenzae type b conjugate vaccines: A phase III randomized double-blind study(2018)11 cited
- → A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children(2018)8 cited
- → Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM 197 -conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study(2016)6 cited
- → Safety, tolerability and immunogenicity of intramuscular administration of PRP-CRM197 Hib vaccine to healthy Japanese children: An open-label trial(2018)3 cited
- → Su1287 – A Phase 1, Randomized, Double-Blind Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Twice Daily Quadruple Therapy Containing Vonoprazan Or Lansoprazole in Healthy Korean Subjects with Helicobacter Pylori Infection(2019)1 cited